View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck &
Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– MSD (tradename of Merck & Co., Inc., Rahway, N.J. USA) and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
September 14, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 27, 2020 |
EFFECT |
EFFECT |
Other |
|
|
August 27, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 25, 2020 |
CORRESP |
CORRESP |
Other |
|
|
August 25, 2020 |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A |
Registration Statements |
|
|
August 25, 2020 |
Amendment to a previously filed 6-K |
6-K/A |
Current Reports |
|
|
August 24, 2020 |
UPLOAD |
UPLOAD |
Other |
|
|
August 20, 2020 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
August 19, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
